Aspirin Response in High Risk Patients With Coronary Artery Disease
Previous studies indicate that patients with cardiovascular disease have a variable response to aspirin. Despite treatment with aspirin a large number of patients suffer a myocardial infarction. This has given rise to the phenomenon "aspirin low-responsiveness". Laboratory aspirin low-responsiveness can be defined as the failure of aspirin to inhibit platelet production of thromboxane A2 or inhibit thromboxane-dependent platelet aggregation. Whether a low platelet response to aspirin results in an increased risk of future thrombotic events is of great clinical significance, but is still unknown.
The investigators hypothesize that patients with a reduced response to aspirin, determined by platelet aggregation using the apparatus Verify Now Aspirin and Multiplate, have a higher risk of thrombosis.
The purpose of this study is to investigate whether a higher incidence of cardiovascular events is found in patients with coronary artery disease (CAD) having a reduced biochemical response to aspirin compared with CAD patients having a normal biochemical response to aspirin. In addition to CAD, all patients have at least one of the following risc factors: previous myocardial infarction, type 2 diabetes mellitus and/or renal insufficiency.
Coronary Artery Disease
Renal Insufficiency, Chronic
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Is a Reduced Biochemical Response to Aspirin Associated With Increased Cardiovascular Morbidity and Mortality in High Risk Patients With Coronary Artery Disease?|
- Combined primary endpoint: Cardiovascular death, acute myocardial infarction, ischaemic stroke [ Time Frame: Evaluation after 3 years ] [ Designated as safety issue: No ]
- Combined secondary endpoint: Cardiovascular death, acute myocardial infarction, ischaemic stroke [ Time Frame: Evaluation after 5 years ] [ Designated as safety issue: No ]
- Single endpoints:cardiovascular death; acute myocardial infarction; ischemic stroke; stent thrombosis; all-cause death [ Time Frame: Evaluation after 3 and 5 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Whole blood, serum, plasma, urine
|Study Start Date:||November 2007|
|Estimated Study Completion Date:||January 2014|
|Primary Completion Date:||January 2011 (Final data collection date for primary outcome measure)|
|Department of Clinical Biochemistry, Aarhus University Hospital, Skejby|
|Aarhus N, Denmark, 8200|
|Principal Investigator:||Anne-Mette Hvas, MD, Ph.D||Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, Denmark|